Recent Advancements Propel Global Nasal Drug Delivery Market Growth

Global nasal drug delivery market is anticipated to grow at a CAGR of 7.8% during the forecast period (2024-2031). Nasal drug delivery is used for various purposes, including treating allergic rhinitis and sinusitis, relieving nasal congestion, treating nasal infections, and providing hormone replacement therapy. It additionally aids in the rapid onset of medication for central nervous system disorders, such as migraine relief. Nasal sprays and drops are preferred for children and elderly patients who struggle with swallowing pills. Advantages of nasal drug delivery include rapid onset, avoidance of first-pass metabolism, and non-invasiveness. 

Browse the full report description of “Nasal Drug Delivery Market Size, Share & Trends Analysis Report by Dosage Form (Gels, Sprays, Drops and Liquids, and Others), by Containers (Non-Pressurized Containers, and Pressurized Containers) by Therapeutic Application (Rhinitis, Nasal Congestion, Asthma, and Others) and by End-User (Hospitals, and Home Health Care) Forecast Period (2024-2031)” at https://www.omrglobal.com/industry-reports/nasal-drug-delivery-market

Recent market developments

• In May 2024, MetP Pharma AG introduced nasal semaglutide using BrainDos Technology, an intranasal delivery system, to combat obesity-related healthcare burden. The drug, used in Ozempic and Wegovy, is an antidiabetic medication for type 2 diabetes and long-term weight management. It functions by powering GLP-1 receptors on beta cells and brain neurons, suppressing hunger, and increasing satiety.

• In July 2024, the National Institutes of Health (NIH) launched a phase 1 trial of a nasal COVID-19 vaccine, MPV/S-2P, as part of the NIAID's Project NextGen. The vaccine uses a murine pneumonia vector to deliver a version of the SARS-CoV-2 spike protein, potentially delivering it to respiratory tract sites.

• In November 2023 Hovione, expanded its nasal drug delivery capabilities by developing innovative nasal powder delivery devices in collaboration with IDC. The devices, one single-use and one multidose offer broad and targeted nasal deposition flexibility, maximum usability, and reliability. It additionally promising for delivering new drugs to the brain to treat central nervous system (CNS) diseases.

Market Coverage

• The market number available for – 2023-2031

• Base year- 2023

• Forecast period- 2024-2031

• Segment Covered- 

o By Dosage Form

o By Containers

o By Therapeutic Application

o By End-User

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape - Aptargroup, Inc., Becton, Dickinson, Co. Novartis AG, Pfizer Inc., and Johnson & Johnson Services, Inc., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Nasal Drug Delivery Market Report Segment

By Dosage Form

• Gels
• Sprays
• Drops and Liquids
• Other (Powders)

By Containers

• Non-Pressurized Containers
• Pressurized Containers

By Therapeutic Application

• Rhinitis
• Nasal Congestion
• Asthma
• Others (Vaccination)

By Therapeutic Application

• Hospitals
• Home Health Care

Global Nasal Drug Delivery Market Report Segment by Region

North America

• United States

• Canada 

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/nasal-drug-delivery-market